HBX 41108 (HBX-41108) is a novel, potent and selective inhibitor of ubiquitin-specific protease 7 (USP7)with anticancer effects. HBX 41108 inhibits USP7 deubiquitinating activity with an IC(50) in the submicromolar range. HBX 41,108 was shown to affect USP7-mediated p53 deubiquitination in vitro and in cells. As RNA interference-mediated USP7 silencing in cancer cells, HBX 41,108 treatment stabilized p53, activated the transcription of a p53 target gene without inducing genotoxic stress, and inhibited cancer cell growth. HBX 41,108 induced p53-dependent apoptosis as shown in p53 wild-type and null isogenic cancer cell lines.

纯度：≥98%

CAS：924296-39-9